Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320357 | 0.94 | MAPK14 (0.42) | MAPK14MAPK11MAPTKDM4EHPGD | |
| SCHEMBL3321269 | 0.94 | MAPK14 (0.41) | MAPK14MAPK11MAPTKDM4EHPGD | |
| SCHEMBL13534495 | 0.89 | MAPK14 (0.46) | MAPK14MAPK11MAPTKDM4EHPGD | |
| SCHEMBL13534496 | 0.88 | MAPK14 (0.45) | MAPK14MAPK11MAPTKDM4EHPGD | |
| SCHEMBL3318071 | 0.88 | GBA1 (0.41) | MAPK14MAPK11MAPTBRD4TP53 | |
| Trifluoroacetic Acid SCHEMBL3318068 | 0.86 | MAPK14 (0.42) | MAPK14MAPK11MAPTKDM4EHPGD | |
| Trifluoroacetic Acid SCHEMBL3314501 | 0.86 | MAPK14 (0.42) | MAPK14MAPK11MAPTKDM4EHPGD | |
| SCHEMBL3345904 | 0.85 | MAPK14 (0.50) | MAPK14MAPK11MAPTHPGDROCK2 | |
| SCHEMBL27635999 | 0.85 | MAPK14 (0.50) | MAPK14MAPK11MAPTKDM4EHPGD | |
| SCHEMBL3317789 | 0.84 | MAPK14 (0.47) | MAPK14MAPK11MAPTROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004298-A1 | P-38 INHIBITORS | DONG QING | 2010-01-07 | — | — | US | claimed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | claimed |
| EP-1635824-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | Novartis AG (CH) | 2006-03-22 | — | — | EP | claimed |
| WO-2005000298-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2005-01-06 | — | — | WO | claimed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | claimed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| US-20100004298-A1 | P-38 INHIBITORS | DONG QING | 2010-01-07 | — | — | US | disclosed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004298-A1 | P-38 INHIBITORS | MAPK8, MAPK1, MAP3K8 | MAPK14 21/4885MAPK11 38/4885MAPT 725/4885 |
| US-20040254236-A1 | P-38 inhibitors | MAPK8, MAP3K8, MAPK1 | MAPK14 12/4885MAPK11 41/4885MAPT 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.